Literature DB >> 20431311

[New data on pancreatic cancer].

Rainer Fietkau1, Volker Heinemann, Helmut Oettle, Wolfram Trudo Knoefel, Andrea Tannapfel.   

Abstract

In pancreatic cancer there is a marked discrepancy between the recorded R0 resection rates and the long-term clinical outcome. Therefore, it seems to be necessary to find additional parameters that will be of more prognostic value here. Differences in how the R classification is applied within the studies are conspicuous. It would seem important to examine standards in histopathological preparation and to return to the 'classical' R classification and, if appropriate, in line with experiences in rectum cancer, to introduce a 'circumferential resection margin'. To obtain optimum long-term survival, a distance of >1.0 mm or even >1.5 mm between tumor and resection margin is required. In too few patients with vascular invasion is the tumor properly removed surgically, even though infiltration of the portal vein or the superior mesenteric vein is not an exclusion criterion according to the S3 guideline. An improvement in the quality of treatment might be achieved by establishing 'high-volume' pancreas centers. The value of perioperative radiochemotherapy (RCT) is currently being examined in several large studies. Adjuvant chemotherapy is standard and is well established in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431311     DOI: 10.1159/000308453

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  3 in total

1.  [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?].

Authors:  J Munding; J Lüttges; I Esposito; A Tannapfel
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

2.  [Pancreatic cancer. Molecular and surgical pathology].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy.

Authors:  M Sinn; R Ganeshan; R Graf; U Pelzer; J M Stieler; J K Striefler; M Bahra; P Wust; H Riess
Journal:  ScientificWorldJournal       Date:  2014-10-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.